References
- Guidance for Industry: Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment. Draft Guidance, August 2010. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071185.pdf [Last accessed 30 May 2012]
- Nichols RL. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother 1999;44:19-23
- Teflaro [package insert]. St. Louis, MO: Forest Pharmaceuticals Inc., 2010
- Corey GR, Wilox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010;51:641-50
- Hatoum HT, Akhras KS, Lin SJ. The attributable clinical and economic burden of skin and skin structure infections in hospitalized patients: a matched cohort study. Diagn Microbiol Infect Dis 2009;64:305-10
- Hernandez PO, Lema S, Tyring SK, et al. Ceftaroline in complicated skin and skin-structure infections. Infect Drug Resist 2010;5:23-35
- Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373-406
- Edelsberg J, Berger A, Weber DJ, et al. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol 2008;29:160-9